Core Insights - BIO-key International, Inc. reported an 18% increase in Q3'24 revenues to $2.1 million, driven by a rise in license revenue from existing customers [2][3][7] - The company achieved a gross profit of $1.7 million with a gross margin of 78.3%, significantly improved from $0.3 million and 18.7% in Q3'23, due to higher license revenue and lower deployment costs [2][8] - The net loss for Q3'24 was reduced to $0.7 million from $1.8 million in Q3'23, reflecting improved revenue and stable operating expenses [2][10] Financial Highlights - Q3'24 revenues rose to $2.1 million from $1.8 million in Q3'23, with license revenue increasing by 52% to $1.4 million [2][7] - Gross profit improved to $1.7 million in Q3'24, compared to $0.3 million in Q3'23, primarily due to a higher proportion of high-margin license revenue [2][8] - Operating expenses were trimmed by $46,000 in Q3'24, reflecting proactive cost management [2][9] - Cash used in operating activities was $2.4 million for the first nine months of 2024, slightly higher than $2.3 million in the prior-year period [2] Recent Developments - The CEO highlighted strong demand from existing customers, with a notable order from a foreign financial services client for biometric identification technology [3][4] - The client has enrolled over 25 million customers using BIO-key technology and is upgrading to a "fingerprint only" solution, enhancing efficiency in customer identification [4][5] - The company plans to publish a whitepaper detailing the benefits of its biometric technology deployment [5] Balance Sheet and Cash Flow - As of September 30, 2024, current assets were approximately $4.6 million, including $1.8 million in cash, compared to $2.6 million at year-end 2023 [11][18] - The company raised $1.9 million in Q3'24 through a warrant inducement agreement, improving its cash position significantly [7][11] - Total liabilities increased to $6.3 million as of September 30, 2024, from $3.5 million at the end of 2023 [18][19]

Core Insights - Bio-Techne Corporation will showcase its latest research products at the AMP 2024 Annual Meeting & Expo, focusing on breast cancer monitoring and carrier screening [1][2] - The company aims to highlight new products that enhance data collection and analysis in molecular diagnostics [2] Product Presentations - The QuantideX® qPCR ESR1 exoMutation Kit will be featured, demonstrating analytical sensitivity of ≤0.1% across 11 ESR1 mutations [3] - The AmplideX® Nanopore Carrier Plus Kit will be presented, which combines PCR chemistry with Oxford Nanopore® technology to identify complex genetic alterations [4] Workshops and Discussions - A session on LDT compliance will address the challenges posed by the FDA's laboratory-developed test rule, discussing various tactical approaches for compliance [5] - Asuragen will host multiple activities and presentations throughout the event, including poster sessions on liquid biopsy surveillance and complex variant genotyping [6][7] Company Overview - Bio-Techne Corporation generated approximately $1.2 billion in net sales in fiscal 2024 and employs over 3,100 people globally [9]

R&D Systems Hematology Controls and Calibrators has completed the Class B Certification under the new European Union In Vitro Diagnostic RegulationThis press release updates the IVDR Classification to Class B from the prior Class C. MINNEAPOLIS, Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators. This certification confirms that the products comply with the regul ...

R&D Systems Hematology Controls and Calibrators has completed the Class C Certification under the new European Union In Vitro Diagnostic RegulationMINNEAPOLIS, Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators. This certification confirms that the products comply with the regulations and guidelines set forth by the European Union for in-vitro diagnostic devices. ...

Core Insights - Bio-Techne Corporation will present at multiple investor conferences in November 2024, including the UBS Global Healthcare Conference, Stifel 2024 Healthcare Conference, and Stephens NASH 2024 Conference [1] Company Overview - Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics [2] - The company generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people worldwide [2]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation in the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden. As part of the conference’s partnering meetings, Tiziana will engage with industry leaders, potenti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange Class B Common Stock, Par Value $0.0001 per share BIO.B New York Stock Exchange For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTIO ...

Bio-Rad Laboratories, Inc. (BIO) posted third-quarter 2024 adjusted earnings per share (EPS) of $2.01, which beat the Zacks Consensus Estimate by 57%. However, the bottom line decreased 13.7% from the prior-year quarter’s level.The quarter’s adjustments primarily eliminate the impacts of certain non-recurring items, such as the amortization of purchased intangibles, restructuring costs and losses from the change in the fair market value of equity securities.The company’s GAAP EPS was $23.34, up 541.2% from ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Norman Schwartz - Chairman of the Board, President & Chief Executive Officer Jon DiVincenzo - President & Chief Operating Officer Roop Lakkaraju - Executive Vice President & Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Leonard - UBS Brandon Couillard - Wells Fargo Jack Meehan - Nephron Research Tycho Pe ...